Reviewed Evidence
Reviewed Study 1: Umbilical Cord Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus Authors: Sun L, Wang D, Liang J, et al. Publication & Date: Arthritis & Rheumatism. 2010;62(8):2467-2475. DOI / Link: https://doi.org/10.1002/art.27548 | PubMed
Reviewed Study 2: The Regulation of the Treg/Th17 Balance by Mesenchymal Stem Cells in Human Systemic Lupus Erythematosus Authors: Wang D, Huang S, Yuan X, et al. Publication & Date: Cellular & Molecular Immunology. 2017;14(5):423-431. DOI / Link: https://doi.org/10.1038/cmi.2015.89 | PubMed
Reviewed Study 3: A Randomised Double-Blind, Placebo-Controlled Trial of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cell for Lupus Nephritis Authors: Deng D, Zhang P, Guo Y, Lim TO Publication & Date: Annals of the Rheumatic Diseases. 2017;76(8):1436-1439. DOI / Link: https://doi.org/10.1136/annrheumdis-2017-211073 | PubMed
Reviewed Study 4: A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD Authors: Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP Publication & Date: Chest. 2013;143(6):1590-1598. DOI / Link: https://doi.org/10.1378/chest.12-2094 | PubMed
Reviewed Study 5: Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Treating Chronic Obstructive Pulmonary Disease: A Pilot Clinical Study Authors: Le Thi Bich P, Nguyen Thi H, Dang Ngo Chau H, et al. Publication & Date: Stem Cell Research & Therapy. 2020;11:60. DOI / Link: https://doi.org/10.1186/s13287-020-1583-4 | PubMed
Supporting Publications
Supporting Publication 1: Efficacy and Safety of Mesenchymal Stromal Cell Transplantation in the Treatment of Autoimmune and Rheumatic Immune Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Authors: Zeng L, Liu C, Wu Y, et al. Publication & Date: Stem Cell Research & Therapy. 2025;16:65. DOI / Link: https://doi.org/10.1186/s13287-025-04184-x | PubMed
Supporting Publication 2: Effect of Mesenchymal Stromal Cell Infusions on Lung Function in COPD Patients With High CRP Levels Authors: Weiss DJ, Segal K, Casaburi R, Hayes J, Tashkin DP Publication & Date: Respiratory Research. 2021;22:142. DOI / Link: https://doi.org/10.1186/s12931-021-01734-8 | PubMed
Scientific Review By: Michael Healey, M.Ed., C.A.S.
Executive Summary & Key Takeaways
- Primary Objective: Assess whether MSC studies in lupus and COPD show consistent suppression of inflammatory cytokines and whether immune changes lead to clinical benefit.
- Evidence Evaluated: Lupus studies mainly used umbilical cord-derived MSCs (UC-MSCs). COPD studies included both bone marrow-derived MSCs (BM-MSCs) and UC-MSCs.
- Key Finding: The evidence supports selective immune modulation, not broad cytokine suppression. Lupus studies showed immune changes, but the strongest controlled trial found no added clinical benefit. In COPD, CRP was the main inflammatory marker, and later subgroup findings were exploratory.
- Safety: MSCs were generally tolerated, but long-term risks and clinical benefits remain uncertain.
Study Overview & Clinical Objectives
For patients researching mesenchymal stem cells and cytokine suppression, this independent review examines what clinical research shows about immune modulation in lupus and COPD, particularly regulatory T cells, Th17 activity, IL-6, TNF-alpha, and CRP.
No meta-analysis identified in this review combines IL-6, TNF-alpha, or regulatory T-cell findings from UC-MSC studies across both lupus and COPD.The available meta-analysis evaluates clinical outcomes in autoimmune and rheumatic diseases and includes no COPD. This review considers cytokine and immune-cell findings from individual human studies alongside the available pooled clinical evidence.
Five principal clinical studies and two supporting publications were evaluated. Weiss 2021 reanalyzed data from the original 2013 randomized COPD trial, while Zeng 2025 pooled results from randomized trials in a meta-analysis.
The evidence differs by disease, study design, and cell source. Lupus studies directly measured Tregs, Th17 cells, TGF-β, TNF-alpha, and IL-6. COPD studies mainly evaluated CRP alongside lung-function and clinical outcomes. Controlled studies were given greater weight for clinical effectiveness, while uncontrolled findings were treated as evidence of possible biological activity rather than proof of benefit.
The principal lupus studies primarily used UC-MSCs. COPD studies included both BM-MSCs and UC-MSCs, with the controlled COPD evidence coming from a bone-marrow-derived product.
Biological Mechanism & Science
MSCs are thought to affect the immune system mainly through signals they release rather than by replacing damaged tissue. These signals may influence T cells, B cells, macrophages, and other immune cells. Proposed effects include increasing regulatory T cells, reducing proinflammatory Th17 activity, changing TGF-β and PGE2 signaling, and altering inflammatory cytokines.
In a 16-patient lupus study, UC-MSC treatment was followed by increased regulatory T cells and a more balanced Th1/Th2 cytokine pattern. Because the study had no control group, it cannot prove that MSCs caused these changes.
Wang studied 30 patients with active, refractory SLE. Regulatory T cells increased at 1 week, 1 month, and 3 months, while Th17 activity decreased at 3, 6, and 12 months. Serum TGF-β increased, TNF-alpha decreased, and IL-6 did not significantly change.
Separate laboratory experiments from the same study showed a more complex picture. IL-6 increased in the cell-culture system while TNF-alpha decreased. Blocking TGF-β reduced the increase in regulatory T cells, and blocking PGE2 reversed the reduction in Th17 cells. Blocking IL-6 did not significantly change either response.
These findings argue against broad cytokine suppression. Instead, MSCs may affect specific immune pathways differently.
Other proposed mechanisms include IL-10 signaling and shifts from inflammatory M1-like macrophages toward more repair-associated M2-like states. However, these effects were not established in the human lupus or COPD studies reviewed here. In COPD, CRP was the main usable inflammatory marker, while broader cytokine analysis was limited by assay detection.
Key Findings & Patient Outcomes
The uncontrolled lupus studies suggest biological activity, but the Deng trial provides the stronger test of clinical effectiveness. Eighteen patients with class III or IV lupus nephritis received either UC-MSCs or placebo while both groups continued standard immunosuppression. Renal remission occurred in 75 percent of MSC recipients and 83 percent of placebo recipients. Complete remission, SLEDAI, BILAG, renal function, complement, and serum albumin also improved similarly in both groups. The trial did not show an added clinical benefit from UC-MSCs.
Zeng’s 2025 meta-analysis included 42 randomized trials and 2,183 participants across autoimmune and rheumatic diseases. In SLE, pooled results favored lower disease activity, but the analysis included only two randomized trials. One was Deng, which showed no added benefit. This means the favorable pooled result appears to depend heavily on the other small SLE trial. Zeng also did not pool IL-6, TNF-alpha, or Treg outcomes and included no COPD studies.
In COPD, the 62-patient randomized Weiss trial found no overall improvement in lung function or quality of life, although patients with higher baseline CRP showed an early CRP decrease. A later post hoc analysis of 29 high-CRP patients found exploratory improvements in FEV1, FVC, and 6-minute walk distance at 120 days, but no benefit in patient-reported outcomes or exacerbations.
The 20-patient UC-MSC COPD pilot also produced mixed results. Symptoms and exacerbation frequency improved, while FEV1 and 6-minute walk distance did not improve significantly overall. CRP fell by about 40 percent at 6 months but did not reach statistical significance. In the 11-patient stage D subgroup, FEV1 also improved at 6 months. Because the study had no control group, these findings do not establish a treatment effect.
Clinical Data Summary
| Study Metric | Study Specification |
|---|---|
| Evidence Set | Five principal clinical studies plus two supporting publications |
| Cohort Relationship | Weiss 2021 is a post hoc reanalysis of the Weiss 2013 COPD cohort; Zeng 2025 is a meta-analysis rather than a separate cohort |
| Participant Counts | Sun SLE N=16; Wang SLE N=30; Deng lupus nephritis N=18; randomized BM-MSC COPD N=62; UC-MSC COPD pilot N=20 |
| Cell Type | Lupus evidence primarily involves UC-MSCs; COPD studies include both BM-MSCs and UC-MSCs, with the controlled COPD trial using BM-MSCs |
| Dose / Key Study Details | Deng: UC-MSCs 2×10⁸ cells with standard immunosuppression; Weiss 2013: four monthly infusions of 100×10⁶ BM-MSCs; Weiss 2021 subgroup: baseline CRP ≥4 mg/L; Le Thi Bich: UC-MSCs 1×10⁶ cells/kg |
| Key Immune Markers | Tregs, Th17 cells, TGF-β, TNF-alpha, IL-6, Th1/Th2-associated cytokines, and CRP |
| Meta-Analysis | 42 RCTs and 2,183 participants across autoimmune and rheumatic diseases; SLE estimates were based on only two RCTs; SLEDAI SMD −2.32 (95% CI −3.59 to −1.06); SLE adverse events RR 0.83 (95% CI 0.28 to 2.51) |
| COPD Biomarker Evidence | Primarily CRP; broader inflammatory cytokine measurements were limited by assay detection in much of the randomized COPD cohort |
| Evidence Summary | Human studies support selective immune modulation, but controlled trials have not established a consistent clinical benefit or a uniform systemic cytokine-suppression signature across lupus and COPD |
Stemedix Clinical Context
From a clinical perspective, the evidence supports immune modulation more clearly than broad cytokine suppression.
In lupus, human studies suggest MSCs may increase regulatory T-cell activity, reduce Th17 responses, and alter signaling involving TGF-β, PGE2, and TNF-alpha. Wang’s study is especially useful because serum TNF-alpha decreased while serum IL-6 did not significantly change. In separate laboratory experiments, IL-6 increased in the presence of UC-MSCs, and blocking IL-6 did not significantly change the Treg or Th17 response. This argues against a simple model in which MSCs broadly suppress inflammatory cytokines.
These biological findings should be separated from evidence of clinical benefit. In the strongest placebo-controlled lupus nephritis trial reviewed here, UC-MSCs did not add benefit beyond standard immunosuppression. Renal remission occurred in 75 percent of the MSC group and 83 percent of the placebo group, while complete remission and changes in SLEDAI, BILAG, renal function, complement, and serum albumin were also similar.
The pooled lupus evidence is less clear. Zeng found a favorable SLEDAI result, but the analysis included only two randomized trials. One was Deng, which did not show added benefit. The pooled result appears to depend heavily on the other small trial. Zeng also did not pool IL-6, TNF-alpha, or Treg outcomes.
Proposed MSC immunomodulation mechanisms in COPD research include changes in inflammatory signaling, macrophage activity, and tissue-repair pathways, but the human studies did not directly prove these mechanisms. CRP was the main usable inflammatory marker.
The randomized BM-MSC trial found no overall pulmonary-function or quality-of-life benefit, although later post hoc analysis of patients with higher baseline CRP found exploratory improvements in FEV1, FVC, and 6-minute walk distance at 120 days.
The uncontrolled UC-MSC pilot also produced mixed results. Symptoms and exacerbation frequency improved, while FEV1 and 6-minute walk distance did not change significantly overall. CRP fell by about 40 percent at 6 months but did not reach statistical significance. A small stage D subgroup showed an additional FEV1 improvement at 6 months.
Overall, these studies suggest possible biological activity, but they do not show that MSCs broadly reduce systemic inflammation or replace established lupus or COPD treatments.
Frequently Asked Questions
What is the immune-modulating mechanism of stem cells in lupus and COPD research?
Human lupus studies suggest MSCs may influence inflammation by increasing regulatory T-cell activity, reducing Th17 responses, and altering TGF-β, PGE2, TNF-alpha, and other immune pathways. COPD evidence is less specific and has primarily evaluated CRP.
How do stem cells reduce IL-6 and TNF-alpha levels?
The human evidence does not show that MSCs consistently reduce both cytokines. In Wang’s lupus study, serum TNF-alpha decreased after UC-MSC treatment while serum IL-6 did not significantly change. In separate laboratory co-culture experiments from the same study, IL-6 increased rather than decreased, and blocking IL-6 did not significantly alter the Treg or Th17 response. These findings argue against a simple model in which MSCs broadly suppress IL-6 and TNF-alpha.
Do umbilical cord MSCs increase regulatory T cells?
Some human lupus studies reported increased regulatory T cells following umbilical cord-derived MSC treatment. In Wang’s study, peripheral Tregs increased at 1 week, 1 month, and 3 months. Separate laboratory experiments supported a role for TGF-β in that response. However, much of the clinical evidence comes from uncontrolled studies, so regulatory T-cell expansion should be considered a mechanistic finding rather than proof of clinical benefit.
What does the meta-analysis show about MSCs and cytokine suppression in lupus?
The 2025 meta-analysis found a favorable pooled SLE disease-activity estimate, but the lupus analysis included only two randomized trials. One was the Deng lupus nephritis trial, in which renal remission occurred in 75 percent of UC-MSC recipients and 83 percent of placebo recipients while both groups received standard immunosuppression. Complete remission and changes in SLEDAI, BILAG, renal function, complement, and serum albumin were also similar between groups.
The favorable pooled SLEDAI result therefore appears to depend heavily on the second small UC-MSC trial rather than reflecting consistent benefit across both randomized studies. The meta-analysis also did not pool IL-6, TNF-alpha, or regulatory T-cell outcomes.
What do COPD studies show about MSC-related inflammation?
COPD studies provide less detailed immune profiling than lupus studies. Proposed mechanisms include effects on inflammatory cytokine signaling, macrophage activity, and tissue-repair pathways, but the reviewed human trials did not directly establish these mechanisms.
The randomized bone-marrow MSC trial identified an early CRP reduction among participants with elevated baseline CRP but did not demonstrate overall pulmonary-function or quality-of-life benefit. A later post hoc high-CRP analysis found exploratory improvements in FEV1, FVC, and 6-minute walk distance at 120 days, without significant improvement in patient-reported outcomes or exacerbations.
In the smaller UC-MSC pilot, symptom scores and exacerbation frequency improved across the full cohort, while FEV1 and 6-minute walk distance did not change significantly. CRP fell by roughly 40 percent from baseline at 6 months but did not reach statistical significance. The small stage D subgroup showed a similar symptom and exacerbation pattern plus a significant FEV1 improvement at 6 months, while CRP and 6-minute walk distance still did not improve significantly. The reviewed COPD studies did not directly demonstrate changes in airway remodeling.
Do MSCs increase IL-10 or shift macrophages from M1 to M2?
IL-10 signaling and macrophage polarization from more inflammatory M1-like states toward more repair-associated M2-like states are proposed MSC immunomodulation mechanisms. However, the reviewed human lupus and COPD studies did not establish either effect clinically.
In the COPD studies, most inflammatory cytokines could not be reliably evaluated because levels were below assay detection limits, leaving CRP as the main usable inflammatory biomarker.
Regulatory Disclaimer
Stemedix provides this review for educational and informational purposes only and represents an academic commentary on published literature. The featured studies evaluate experimental procedures and primarily preclinical models. Regenerative cell therapies and extracellular vesicle therapies discussed are non-FDA-approved treatments unless explicitly stated otherwise. Consult a board-certified physician before making medical decisions.
References
1. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467-2475. doi:10.1002/art.27548. https://pubmed.ncbi.nlm.nih.gov/20506343/ 2. Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14(5):423-431. doi:10.1038/cmi.2015.89. https://pubmed.ncbi.nlm.nih.gov/26435067/ 3. Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436-1439. doi:10.1136/annrheumdis-2017-211073. https://pubmed.ncbi.nlm.nih.gov/28478399/ 4. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590-1598. doi:10.1378/chest.12-2094. https://pubmed.ncbi.nlm.nih.gov/23172272/ 5. Le Thi Bich P, Nguyen Thi H, Dang Ngo Chau H, et al. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study. Stem Cell Res Ther. 2020;11:60. doi:10.1186/s13287-020-1583-4. https://pubmed.ncbi.nlm.nih.gov/32054512/ 6. Zeng L, Liu C, Wu Y, et al. Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025;16:65. doi:10.1186/s13287-025-04184-x. https://pubmed.ncbi.nlm.nih.gov/39934871/ 7. Weiss DJ, Segal K, Casaburi R, Hayes J, Tashkin DP. Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels. Respir Res. 2021;22:142. doi:10.1186/s12931-021-01734-8. https://pubmed.ncbi.nlm.nih.gov/33964910/